BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18931548)

  • 1. Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors.
    Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee GK; Lee KH
    Urol Int; 2008; 81(3):306-11. PubMed ID: 18931548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract.
    Krabbe LM; Bagrodia A; Haddad AQ; Kapur P; Khalil D; Hynan LS; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
    J Urol; 2015 May; 193(5):1486-93. PubMed ID: 25451830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract.
    Kang CH; Yu TJ; Hsieh HH; Yang JW; Shu K; Huang CC; Chiang PH; Shiue YL
    Cancer; 2003 Oct; 98(8):1620-6. PubMed ID: 14534877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of KI-67 proliferation index in transitional cell carcinoma of renal pelvis and ureter].
    Korneev IA
    Vopr Onkol; 2005; 51(2):211-5. PubMed ID: 16223003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy.
    Wang P; Luo JD; Wu WF; Wang S; Cai SL; Shen BH; Shi SF; Wei KX; Zhang ZG; Chen ZD
    Braz J Med Biol Res; 2007 Jul; 40(7):979-84. PubMed ID: 17653452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factors and oncogene products in transitional cell carcinoma.
    Nakanishi K; Kawai T; Suzuki M; Torikata C
    Mod Pathol; 1996 Mar; 9(3):292-7. PubMed ID: 8685230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers.
    Novara G; De Marco V; Dalpiaz O; Galfano A; Bouygues V; Gardiman M; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Int J Urol; 2009 Feb; 16(2):187-91. PubMed ID: 19054165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma.
    Cosentino M; Palou J; Gaya JM; Breda A; Rodriguez-Faba O; Villavicencio-Mavrich H
    World J Urol; 2013 Feb; 31(1):141-5. PubMed ID: 22552732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor.
    Palou J; Rodríguez-Rubio F; Huguet J; Segarra J; Ribal MJ; Alcaraz A; Villavicencio H
    J Urol; 2005 Sep; 174(3):859-61; discussion 861. PubMed ID: 16093970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
    Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
    Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel p53/p130 axis in bladder tumors.
    Mudryj M; Reay E; Beckett L; Dandekar S; deVere White R; Gandour-Edwards R
    Urology; 2007 Sep; 70(3):608-12. PubMed ID: 17905135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage].
    San Miguel Fraile P; Antón Badiola I; Ortiz Rey JA; Alvarez Alvarez C; Fernández Costas A; Lago Fernández M; Pelaez Boismorand E; Zungri Telo E; De La Fuente Buceta A
    Actas Urol Esp; 2003 Sep; 27(8):587-93. PubMed ID: 14587233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma.
    Murta CB; Antunes AA; Dall'Oglio MF; Mosconi A; Leite KR; Srougi M
    Clinics (Sao Paulo); 2008 Apr; 63(2):223-8. PubMed ID: 18438577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Milenkovic-Petronic D; Vuksanovic A; Dragicevic D; Bumbasirevic U; Tulic C
    Int Urol Nephrol; 2011 Sep; 43(3):729-35. PubMed ID: 21350863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
    J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.